More and more for us, it simply means being a bit creative. We tend to tap international sources a lot more than we used to, which is not a bad thing. Private money is tough these days. Over the last two to three years especially, as I think as everyone would appreciate, there hasn't been a lot of it around.
The other thing is that in the space I operate in, venture capital funding in Canada is problematic at the best of times, and over the last few years it has been virtually non-existent. Therefore, most of the technologies go south, where you don't have that issue with biotech.